title: Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.
abstract: OBJECTIVE
  To evaluate the clinical characteristics, treatment and outcomes of patients with osteoarticular infections (OAIs) associated with Staphylococcus aureus bacteraemia (SAB).
  
  
  METHODS
  The clinical characteristics and outcomes for patients with OAI were described using a post hoc analysis of an open label, randomized trial comparing daptomycin with standard therapy (vancomycin or anti-staphylococcal penicillin with initial gentamicin) for the treatment of SAB.
  
  
  RESULTS
  OAI occurred in 32 of 121 patients (21 daptomycin and 11 standard therapy) with complicated SAB (18 septic arthritis, 9 vertebral osteomyelitis and 7 others). Two patients had osteomyelitis in more than one site. Success rates seen in two groups were as follows: vertebral osteomyelitis [3/5 (60%) daptomycin versus 0/2 (0%) comparator], septic arthritis [7/11 (64%) versus 3/5 (60%)], sternal osteomyelitis [3/3 (100%) versus 1/2 (50%)] and long bone osteomyelitis [0/1 (0%) versus 1/1 (100%)]. Success rates in both treatment groups improved with surgical therapy. Creatine phosphokinase elevations to >500 IU/L occurred in one patient on daptomycin who discontinued therapy, whereas renal impairment developed in three patients on standard therapy, two of whom discontinued therapy. Two patients treated with daptomycin and one patient on vancomycin had increases in S. aureus MICs to daptomycin and vancomycin, respectively. Three patients treated with daptomycin died following completion of therapy, with mortality attributed to multiple co-morbid conditions and inadequate debridement of OAIs in these patients. No deaths were reported in the standard therapy group.
  
  
  CONCLUSIONS
  Daptomycin may be considered an alternative to standard therapy in the treatment of patients with complicated SAB and OAI.
authors.affiliation: Division of Infectious Diseases, Duke Clinical Research Institute, Durham, NC, USA. lalan002@mc.duke.edu
authors.forename: T
authors.initials: T
authors.lastname: Lalani
authors.forename: H W
authors.initials: HW
authors.lastname: Boucher
authors.forename: S E
authors.initials: SE
authors.lastname: Cosgrove
authors.forename: V G
authors.initials: VG
authors.lastname: Fowler
authors.forename: Z A
authors.initials: ZA
authors.lastname: Kanafani
authors.forename: G A
authors.initials: GA
authors.lastname: Vigliani
authors.forename: M
authors.initials: M
authors.lastname: Campion
authors.forename: E
authors.initials: E
authors.lastname: Abrutyn
authors.forename: D P
authors.initials: DP
authors.lastname: Levine
authors.forename: C S
authors.initials: CS
authors.lastname: Price
authors.forename: S J
authors.initials: SJ
authors.lastname: Rehm
authors.forename: G R
authors.initials: GR
authors.lastname: Corey
authors.forename: A W
authors.initials: AW
authors.lastname: Karchmer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017576:Daptomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin